Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. [electronic resource]
Producer: 20190409Description: 1238-1245 p. digitalISSN:- 1941-837X
- Antigens, CD19 -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Biological Products
- Cost-Benefit Analysis
- Decision Support Techniques
- Fees, Pharmaceutical -- statistics & numerical data
- Health Expenditures -- statistics & numerical data
- Humans
- Immunotherapy, Adoptive -- adverse effects
- Lymphoma, B-Cell -- drug therapy
- Models, Econometric
- Quality-Adjusted Life Years
- Recurrence
- Salvage Therapy -- economics
- Survival Analysis
- United States
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.